|
Title
|
|
|
|
Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Objective. To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen. Design. Prospective 36 months cohort study of patients switched to zidovudine/stavudine plus didanosine plus lopinavir/ritonavir capsules as second-line regimen. Methodology. Structured interview, medical examination, and laboratory assessment performed every 6 months. Results. We enrolled 40 patients; 1 died and 3 were lost to follow-up. Median CD4+ count at baseline was 108 cell/µL, median log viral load was 4.8 copies/mL. Sixteen (40%) patients had baseline genotypic resistant test, 14 (87%) had lamivudine resistance mutations, and all had NNRTIs resistance mutations. At month 36, 82% of the patients achieved viral suppression (<400 copies/ mL) and the median increase in CD4+ count was 214 cell/µL, (interquartile range: 128-295). Twenty-five patients (62%) experienced at least one adverse event. Conclusions. Our study confirms lopinavir/ ritonavir-based second-line regimen but with a high rate of toxicities. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of the International Association of Physicians in AIDS Care. - Chicago, Ill.
| |
|
Publication
|
|
|
|
Chicago, Ill.
:
2009
| |
|
ISSN
|
|
|
|
1545-1097
| |
|
DOI
|
|
|
|
10.1177/1545109708328538
| |
|
Volume/pages
|
|
|
|
8
:1
(2009)
, p. 52-59
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|